Clinical Trial Update: Mosunetuzumab in Combination With Pirtobrutinib in Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia (MPOWER) [Phase 2]

View source ↗

Summary

This document provides an update on a Phase 2 clinical trial evaluating the combination of mosunetuzumab with pirtobrutinib in patients with relapsed or refract…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Waldenström Macroglobulinemia

Drugs mentioned

• Mosunetuzumab (mosunetuzumab)
• Pirtobrutinib (pirtobrutinib)

Snippet

Sponsor: University of Utah | Conditions: Waldenstrom Macroglobulinemia | Phase 2 | Status: NOT_YET_RECRUITING